FIBROSIS PULMONAR IDIOPATICA PDF

Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Por otra parte, probablemente no se asocia a eventos adversos serios. Todos los estudios midieron el desenlace mortalidad, exacerbaciones agudas y eventos adversos serios. El resumen de los resultados es el siguiente:.

Author:Dolmaran Juzuru
Country:Ethiopia
Language:English (Spanish)
Genre:Science
Published (Last):19 October 2006
Pages:154
PDF File Size:3.95 Mb
ePub File Size:7.80 Mb
ISBN:115-5-96458-405-8
Downloads:35512
Price:Free* [*Free Regsitration Required]
Uploader:JoJodal



Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Por otra parte, probablemente no se asocia a eventos adversos serios. Todos los estudios midieron el desenlace mortalidad, exacerbaciones agudas y eventos adversos serios. El resumen de los resultados es el siguiente:. Su principal desarrollo es la base de datos Epistemonikos www. Idiopathic pulmonary fibrosis has poor prognosis and effective therapies are scarce. In the search for treatments that can modify the course of the disease, nintedanib BIBF , a tyrosine kinase inhibitor, has emerged as an alternative.

However, its role is still unclear. To answer this question, we searched in Epistemonikos database, which is maintained by screening multiple sources of information. We identified seven systematic reviews including seven randomized trials overall.

We extracted data, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. We concluded nintedanib probably decreases the risk of acute exacerbations, and might reduce mortality in idiopathic pulmonary fibrosis.

On the other hand, it is probably not associated with serious adverse events. Is nintedanib effective for idiopathic pulmonary fibrosis?. Medwave ;17 Suppl2 :e doi: Ficha PubMed. Contacto English Email: Clave:. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology.

Eur Respir J. Incidence and prevalence of idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Ann Intern Med. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials.

Respir Med. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.

BMC Pharmacol Toxicol. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis. BMC Pulm Med. Horizon Scanning Review. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

Pulm Pharmacol Ther. Safety and efficacy of BIBF in idiopathic pulmonary fibrosis. Link ClinicalTrials. Safety and efficacy of BIBF at high dose in idiopathic pulmonary fibrosis patients. Roll over study from Follow up Study From An Update of the Clinical Practice Guideline. Nintedanib for idiopathic pulmonary fibrosis — first line.

EU Clinical Trials Register. Acceso Webactivo. Medwave Estudios. ISSN Nintedanib probablemente no se asocia a eventos adversos serios. Sobre los desenlaces incluidos en este resumen. Por ej. Consideraciones de recursos. Se trata de una terapia de alto costo y cuya disponibilidad no es amplia.

EL FUTURO DEL CAPITALISMO LESTER THUROW PDF

Is Nintedanib Effective for Idiopathic Pulmonary Fibrosis?

Idiopathic pulmonary fibrosis has poor prognosis and effective therapies are scarce. In the search for treatments that can modify the course of the disease, nintedanib BIBF , a tyrosine kinase inhibitor, has emerged as an alternative. However, its role is still unclear. To answer this question, we searched in Epistemonikos database, which is maintained by screening multiple sources of information. We identified seven systematic reviews including seven randomized trials overall. We extracted data, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. We concluded nintedanib probably decreases the risk of acute exacerbations, and might reduce mortality in idiopathic pulmonary fibrosis.

AUGIAS SEGRETI DI ROMA PDF

2005, Número 4

Archivos de Bronconeumologia http: www. Other types of articles such as reviews, editorials, special articles, clinical reports, and letters to the Editor are also published in the Journal. It is a monthly Journal that publishes a total of 12 issues, which contain these types of articles to different extents. All manuscripts are sent to peer-review and handled by the Editor or an Associate Editor from the team.

BIVOLTINE SILKWORM PDF

After the three revisions done by Cochrane for the last ten years, it has been demonstrated that most of the clinical assays performed whit corticosteroids, immunomodulators and antifibrotic drugs have shown inconclusive results for the treatment of idiopathic pulmonary fibrosis. To date, only pirfenidone has proved to have significant efficacy in controlled clinical trials in the treatment of this disease. At present, a large number of new drugs are being tested, which offers a new perspective in some ways optimistic concerning the future treatment of this disease.. ISSN: Future prospects in the treatment of idiopathic pulmonary fibrosis. Descargar PDF. Ferran Morell??

Related Articles